Neumora Therapeutics Commences the P-Ib Trial of NMRA-511 to Treat Agitation Due to Alzheimer’s Disease
Shots:
- The P-Ib trial will be conducted in two parts with Part A assessing the safety, tolerability & PK of NMRA-511 (V1aR antagonist) among healthy elderly individuals (n=~8) and Part B determining the safety, tolerability & efficacy of NMRA-511 (20mg, BID) among individuals (n=~88) with agitation associated with dementia because of AD
- The 1EP of the study includes a change in the Cohen-Mansfield Agitation Inventory total score at wk.8. Topline data is anticipated in H2’25
- Neumora's concluded P-Ia single ascending dose (SAD)/multiple ascending dose (MAD) trial of NMRA-511 (5,10, 15, 20 & 40 mg) among healthy adults (n=92) found the drug well tolerated without any SAEs. Data is expected at upcoming conferences
Ref: Neumora Therapeutics | Image: Neumora Therapeutics
Related News:- Takeda and AC Immune Collaborate for ACI-24.060 to Treat Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
